Overactive bladder

Korean Journal of Urology

Volumn 48, Issue 12, 2007, Pages 1191-1208

  Lee, Kyu Sung ^a   Lee, Young Suk ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Behavioral therapy; Overactive bladder; Pathophysiology; Pharmacological therapy; Surgical therapy

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BOTULINUM TOXIN; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DARIFENACIN; DESMOPRESSIN; DIURETIC AGENT; DOXAZOSIN; DULOXETINE; ESTRADIOL; ESTROGEN; IMIPRAMINE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NARCOTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; OXYBUTYNIN; PRAZOSIN; PROPIVERINE; PROSTAGLANDIN INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SOLIFENACIN; TAMSULOSIN; TERAZOSIN; TOLTERODINE; TROSPIUM CHLORIDE; UNINDEXED DRUG;

AWARENESS; BEDTIME DOSAGE; BEHAVIOR THERAPY; BLADDER CAPACITY; BLADDER CONTRACTION; BLADDER SURGERY; CONSERVATIVE TREATMENT; DEPRESSION; DETRUSOR DYSSYNERGIA; EVENING DOSAGE; EVIDENCE BASED PRACTICE; HEART BUNDLE BRANCH BLOCK; HUMAN; HYPONATREMIA; KOREA; NEUROMODULATION; NOCTURIA; ORTHOSTATIC HYPOTENSION; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SYMPTOM; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE;

EID: 38049127229     PISSN: 04944747     EISSN: None     Source Type: Journal    
DOI: 10.4111/kju.2007.48.12.1191     Document Type: Review

References (100)

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78
2. Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 2006;175:191-4
3. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78
4. Brading AF. A myogenic basis for the overactive bladder. Urology 1997;50:57-67
5. Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. IV. Bladder outlet obstruction. J Urol 1993;150:1681-95
6. Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. III. Detrusor overactivity. J Urol 1993;150:1668-80
7. de Groat WC. A neurologic basis for the overactive bladder. Urology 1997;50(6A Suppl):36-52
8. Drake MJ, Mills IW, Gillespie JI. Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function. Lancet 2001;358:401-3
9. Zorn BH, Montgomery H, Pieper K, Gray M, Steers WD. Urinary incontinence and depression. J Urol 1999;162:82-4
10. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
11. Melville JL, Katon W, Lentz G, Miller J, Fenner D. Prevalence of comorbid psychiatric illness and its impact on symptom perception, quality of life, and functional status in women with urinary incontinence. Am J Obstet Gynecol 2002;187:80-7
12. Lee KS, Na YG, Dean-McKinney T, Klausner AP, Tuttle JB, Steers WD. Alterations in voiding frequency and cystometry in the clomipramine induced model of endogenous depression and reversal with fluoxetine. J Urol 2003;170:2067-71
13. Ouslander JG. Management of overactive bladder. N Engl J Med 2004;350:786-99
14. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-6
15. Irwin DE, Milsom I, Hanskaar S, Reilly K, Kopp Z, Hetschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50: 1306-14
16. Komaroff AL, Fagioli LR, Doolittle TH, Gandek B, Gleit MA, Guerriero RT, et al. Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups. Am J Med 1996;101:281-90
17. Kelleher CJ, Reese PR, Pleil AM, Okano GJ. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002;8(19 Suppl): S608-15
18. Liberman JN, Hunt TL, Stewart WF, Wein A, Zhou Z, Herzog AR, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 2001;57:1044-50
19. Kobelt G. Economic considerations and outcome measurement in urge incontinence. Urology 1997;50(6A Suppl):100-7
20. Brown JS, Posner SF, Stewart AL. Urge incontinence: new health-related quality of life measures. J Am Geriatr Soc 1999;47:980-8
21. DuBeau CE, Kiely DK, Resnick NM. Quality of life impact of urge incontinence in older persons: a new measure and conceptual structure. J Am Geriatr Soc 1999;47:989-94
22. Dugan E, Cohen SJ, Bland DR, Preisser JS, Davis CC, Suggs PK, et al. The association of depressive symptoms and urinary incontinence among older adults. J Am Geriatr Soc 2000;48: 413-6
23. Steers WD, Lee KS. Depression and incontinence. World J Urol 2001;19:351-7
24. Brown JS, Vittinghoff E, Wyman JF, Stone KL, Nevitt MC, Ensrud KE, et al. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 2000;48:721-5
25. Dmochowski RR, Sanders SW, Appell RA, Nitti VW, Davila GW. Bladder-health diaries: an assessment of 3-day vs 7-day entries. BJU Int 2005;96:1049-54
26. Marks LS, Dorey FJ, Macairan ML, Park C, deKernion JB, Three-dimensional ultrasound device for rapid determination of bladder volume. Urology 1997;50:341-8
27. Gormley EA, Griffiths DJ, McCracken PN, Harrison GM, McPhee MS. Effect of transurethral resection of the prostate on detrusor instability and urge incontinence in elderly males. Neurourol Urodyn 1993;12:445-53
28. Nitti VW, Raz S. Obstruction following anti-incontinence procedures: diagnosis and treatment with transvaginal urethrolysis. J Urol 1994;152:93-8
29. Goode PS. Behavioral and drug therapy for urinary incontinence. Urology 2004;63(3 Suppl 1):58-64
30. Song C, Park JT, Heo KO, Lee KS, Choo MS. Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study. J Korean Med Sci 2006;21:1060-3
31. Fantl JA, Wyman JF, McClish DK, Harkins SW, Elswick RK, Taylor JR, et al. Efficacy of bladder training in older women with urinary incontinence. JAMA 1991;265:609-13
32. Burgio KL, Goode PS, Locher JL, Umlauf MG, Roth DL, Richter HE, et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. JAMA 2002;288:2293-9
33. Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, Dombrowski M, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 1998;280:1995-2000
34. Jarvis GJ, Millar DR. Controlled trial of bladder drill for detrusor instability. Br Med J 1980;281:1322-3
35. Andersson KE. Bladder activation: afferent mechanisms. Urology 2002;59(5 Suppl 1):43-50
36. Yoshida M, Inadome A, Murakami S, Miyamae K, Iwashita H, Otani M, et al. Effects of age and muscle stretching on acetylcholine release in isolated human bladder smooth muscle. J Urol 2002;167:40[abstract 160]
37. Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003;78:687-95
38. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001;57:414-21
39. Wiedemann A, Fusgen I, Hauri D. New aspects of therapy with trospium chloride for urge incontinence. Eur J Geriatrics 2002;3:41
40. Rovner ES. Trospium chloride in the management of overactive bladder. Drugs 2004;64:2433-46
41. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder, Eur Urol 2004;45: 420-9
42. Chapple CR. Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder, Expert Opin Investig Drugs 2004;13:1493-500
43. Chapple C, Dubeau C, Ebinger U, Rekeda L, Viegas A. Darifenacin treatment of patients >/= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin 2007; 23:2347-58
44. Smith CM, Wallis RM. Charactetisation of [3H]-darifenacin as a novel radioligand for the study of muscarinic M3 receptors. J Recept Signal Transduct Res 1997;17:177-84
45. Chapple CR, Arano P, Bosch JL, De Ridder D, Kramer AE, Ridder AM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 2004;93:71-7
46. Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70
47. Ekstrom B, Andersson KE, Mattiasson A. Urodynamic effects of intravesical instillation of atropine and phentolamine in patients with detrusor hyperactivity. J Urol 1993;149:155-8
48. Enskat R, Deaney CN, Glickman S. Systemic effects of intravesical atropine sulphate. BJU Int 2001;87:613-6
49. Lose G, Nørgaard JP. Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor. BJU Int 2001; 87:767-73
50. Kasabian NG, Vlachiotis JD, Lais A, Klumpp B, Kelly MD, Siroky MB, et al. The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia. J Urol 1994;151:944-5
51. Palmer LS, Zebold K, Firlit CF, Kaplan WE. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population. J Urol 1997;157:638-40
52. Appell RA, Chancellor MB, Zobrist RH, Thomas H, Sanders SW. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 2003;78:696-702
53. Chancellor MB, Appell RA, Sathyan G, Gupta SK. A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate. Clin Ther 2001;23:753-60
54. Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003;62:237-42
55. Dmochowski RR, Davila GW, Zinner NR, Gittelman MC, Saltzstein DR, Lyttle S, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002;168:580-6
56. Haruno A. Inhibitory effects of propiverine hydrochloride on the agonist-induced or spontaneous contractions of various isolated muscle preparations. Arzneimittelforschung 1992;42: 815-7
57. Tokuno H, Chowdhury JU, Tomita T. Inhibitory effects of propiverine on rat and guinea-pig urinary bladder muscle. Naunyn Schmiedebergs Arch Pharmacol 1993;348:659-62
58. Dorschner W, Stolzenburg JU, Griebenow R, Halaska M, Schubert G, Murtz G, et al. Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study. Eur Urol 2000;37:702-8
59. Oka M, Kimura Y, Itoh Y, Sasaki Y, Taniguchi N, Ukai Y, et al. Brain pertussis toxin-sensitive G proteins are involved in the flavoxate hydrochloride-induced suppression of the micturition reflex in rats. Brain Res 1996;727:91-8
60. Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005;48:5-26
61. Choo MS, Song C, Kim JH, Choi JB, Lee JY, Chung BS, et al. Changes in overactive bladder symptoms after discontinuation of successful 3-month treatment with an antimuscarinic agent: a prospective trial. J Urol 2005;174:201-4
62. Maggi CA, Borsini F, Lecci A, Giuliani S, Meli P, Gragnani L, et al. Effect of acute or chronic administration of imipramine on spinal and supraspinal micturition reflexes in rats. J Pharmacol Exp Ther 1989;248:278-85
63. Glazener CM, Evans JH, Peto RE. Tricyclic and related drugs for nocturnal enuresis in children. Cochrane Database Syst Rev 2003:CD002117
64. Giardina EG, Bigger JT Jr, Glassman AH, Perel JM, Kantor SJ. The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations. Circulation 1979;60:1045-52
65. Castleden CM, Duffin HM, Gulati RS. Double-blind study of imipramine and placebo for incontinence due to bladder instability. Age Ageing 1986;15:299-303
66. Hunsballe JM, Djurhuus JC. Clinical options for imipramine in the management of urinary incontinence. Urol Res 2001;29: 118-25
67. Darblade B, Behr-Roussel D, Oger S, Hieble JP, Lehret T, Gorny D, et al. Effects of potassium channel modulators on human detrusor smooth muscle myogenic phasic contractile activity: potential therapeutic targets for overactive bladder. Urology 2006;68:442-8
68. Tertyshnikova S, Knox RJ, Plym MJ, Thalody G, Griffin C, Neelands T, et al. BL-1249 [(5,6,7,8-tetrahydro-naphthalen-1-y1)-[2- (1H-tetrazol-5-y1)-phenyl]-amine]: a putative potassium channel opener with bladder-relaxant properties. J Pharmacol Exp Ther 2005;313:250-9
69. Schwinn DA, Price PR. Molecular pharmacology of human a1-adrenergic receptors: unique features of the a1-subtype. Eur Urol 1999;36(Suppl 1):7-10
70. Ohtake A, Ukai M, Saitoh C, Sonoda R, Noguchi Y, Okutsu H, et al. Effect of tamsulosin on spontaneous bladder contraction in conscious rats with bladder outlet obstruction: comparison with effect on intraurethral pressure. Eur J Pharmacol 2006;545:185-91
71. Tatemichi S, Akiyama K, Kobayashi M, Yamazaki Y, Yokoyama O, Uruno T. A selective alpha1A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia. J Urol 2006;176:1236-41
72. Trevisani M, Campi B, Gatti R, Andre E, Materazzi S, Nicoletti P, et al. The influence of alpha1-adrenoreceptors on neuropeptide release from primary sensory neurons of the lower urinary tract. Eur Urol 2007;52:901-8
73. Yokoyama O, Yusup A, Oyama N, Aoki Y, Miwa Y, Akino H. Improvement in bladder storage function by tamsulosin depends on suppression of C-fiber urethral afferent activity in rats. J Urol 2007;177:771-5
74. Yamanishi T, Yasuda K, Kitahara S, Nakai H, Yoshida K, Iizuka H. Effects of 138-355, a beta3-adrenoceptor selective agonist, on relaxation of the human detrusor muscle in vitro. Neurourol Urodyn 2006;25:815-9
75. Biers SM, Reynard JM, Brading AF. The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder. BJU Int 2006;98:1310-4
76. Murakami S, Chapple CR, Akino H, Sellers DJ, Chess-Williams R. The role of the urothelium in mediating bladder responses to isoprenaline. BJU Int 2007;99:669-73
77. Green SA, Alon A, Ianus J, McNanghton KS, Tozzi CA, Reiss TF. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. J Urol 2006;176:2535-40
78. Cardozo LD, Stanton SL, Robinson H, Hole D. Evaluation of flurbiprofen in detrusor instability. Br Med J 1980;280:281-2
79. Palmer J. Report of a double-blind crossover study of flurbiprofen and placebo in detrusor instability. J Int Med Res 1983;11(Suppl 2):11-7
80. Liu L, Mansfield KJ, Kristiana I, Vanx KJ, Millard RJ, Burcher E. The molecular basis of urgency: regional difference of vanilloid receptor expression in the human urinary bladder. Neurourol Urodyn 2007;26:433-8
81. Ishizuka O, Mattiasson A, Andersson KE. Urodynamic effects of intravesical resiniferatoxin and capsaicin in conscious rats with and without outflow obstruction. J Urol 1995;154:611-6
82. Kuo HC, Liu HT, Yang WC. Therapeutic effect of multiple resiniferatoxin intravesical instillations in patients with refractory detrusor overactivity: a randomized, double-blind, placebo controlled study. J Urol 2006;176:641-5
83. Apostolidis A, Gonzales GE, Fowler CJ. Effect of intravesical Resiniferatoxin (RTX) on lower urinary tract symptoms, urodynamic parameters, and quality of life of patients with urodynamic increased bladder sensation. Eur Urol 2006;50:1299-305
84. Andrade EL, Ferreira J, Andre E, Calixto JB. Contractile mechanisms coupled to TRPA1 receptor activation in rat urinary bladder. Biochem Pharmacol 2006;72:104-14
85. Dmochowski RR. Duloxetine: a summary of published clinical experience. Rev Urol 2004;6(Suppl 3):S56-63
86. de Miguel F, Chancellor MB. [Pittsburgh experience with botulinum toxin A injection]. Actas Urol Esp 2006;30:310-4
87. Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 2006;68:1193-7
88. Lucioni A, Rapp DE, Gong EM, Fedunok P, Bales GT. Intravesical botulinum type A toxin injection in patients with overactive bladder: trigone versus trigone-sparing injection. Can J Urol 2006;13:3291-5
89. Ruffion A, Capelle O, Paparel P, Leriche B, Leriche A, Grise P. What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int 2006;97: 1030-4
90. Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006;49:644-50
91. Coyne KS, Tubaro A, Brubaker L, Bavendam T. Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. Urology 2006;68:9-16
92. Brubaker L, Chapple C, Coyne KS, Kopp Z. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology 2006;68:3-8
93. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006;296: 2319-28
94. Choe JH, Choo MS, Lee KS. Symptom change in women with overactive bladder after extracorporeal magnetic stimulation: a prospective trial. Int Urogynecol J Pelvic Floor Dysfunct 2007;18:875-80
95. Schmidt RA. Advances in genitourinary neurostimulation. Neurosurgery 1986;19:1041-4
96. Tanagho EA, Schmidt RA. Electrical stimulation in the clinical management of the neurogenic bladder. J Urol 1988;140:1331-9
97. Seif C, van der Horst C, Naumann CM, Junemann KP, Bosch R, Buller J, et al. [Pudendal nerve stimulation therapy of the overactive bladder - an alternative to sacral neuromodulation?]. Aktuelle Urol 2005;36:234-8
98. Oerlemans DJ, van Kerrebroeck PE. Sacral nerve stimulation for neuromodulation of the lower urinary tract. Neurourol Urodyn 2007; [Epub ahead of print]
99. Shaker HS, Hassouna M. Sacral nerve root neuromodulation: an effective treatment for refractory urge incontinence. J Urol 1998;159:1516-9
100. Chung JW, Han DH, Lee KS. Efficacy and safety of sacral neuromodulation (interstim) for the treatment of refractory overactive bladder symptoms and chronic pelvic pain. Korean J Urol 2007;48:701-5